Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Tezepelumab

- PMLiVE

Amgen hit as Kyprolis fails myeloma study

Inability to improve overall survival could dent expanded use prospects

- PMLiVE

Amgen closes on second-line use for Kyprolis

Multiple myeloma therapy posts positive interim phase III results

- PMLiVE

Amgen cuts workforce and facilities despite profit leap

US biopharma plans 12-15 per cent workforce reduction

- PMLiVE

Amgen launches bowel cancer web portal in Spain

Aims to help healthcare professionals understand about personalised medicine

- PMLiVE

Amgen’s Sensipar follow-up clears phase III trial

AMG 416 meets objectives in hyperparathyroidism

- PMLiVE

Amgen and Boehringer drugs win FDA breakthrough status

Leukaemia drug and Pradaxa antidote will benefit from accelerated regulatory processes

Kite Pharma once again looks to Amgen

William Go and Jeff Aycock fourth and fifth senior figures to join from Amgen this year

- PMLiVE

AZ licenses asthma infection drug from Synairgen

Boosts respiratory portfolio with $232m deal

- PMLiVE

Amgen appoints ex US surgeon general

Steven Galson is also a former director of the FDA’s Center for Drug Evaluation and Research

- PMLiVE

Amgen and AZ’s psoriasis antibody clears phase III trial

Brodalumab meets its targets in the AMAGINE-1 study

- PMLiVE

Amgen cholesterol antibody shines in rare disease trial

Evolocumab passes late-stage study

- PMLiVE

GSK set to file severe asthma candidate by year-end

Mepolizumab reduces frequency of exacerbations in late-stage trial

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links